Zyla Life Sciences Payment for Contingent Consideration Liability, Financing Activities
Zyla Life Sciences reported Payment for Contingent Consideration Liability, Financing Activities of $1.60 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities · last filed 2020-05-14
- Zyla Life Sciences payment for contingent consideration liability, financing activities for the quarter ending 2020-03-31 was $1.60M.
| Period end | Payment for Contingent Consideration Liability, Financing Activities 3 month | Payment for Contingent Consideration Liability, Financing Activities 11 month |
|---|---|---|
| 2020-03-31 | $1.60M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $1.88M 10-K · filed 2020-03-26 |